Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/183119
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Salto Alejandre, Sonsoles | - |
dc.contributor.author | Palacios Baena, Zaira R. | - |
dc.contributor.author | Arribas, José Ramón | - |
dc.contributor.author | Berenguer, Juan | - |
dc.contributor.author | Carratalà, Jordi | - |
dc.contributor.author | Jarrín, Inmaculada | - |
dc.contributor.author | Ryan, Pablo | - |
dc.contributor.author | Miguel Montero, Marta de | - |
dc.contributor.author | Rodríguez Baño, Jesús | - |
dc.contributor.author | Pachón, Jerónimo | - |
dc.date.accessioned | 2022-02-11T16:41:34Z | - |
dc.date.available | 2022-02-11T16:41:34Z | - |
dc.date.issued | 2021-12-01 | - |
dc.identifier.issn | 0753-3322 | - |
dc.identifier.uri | http://hdl.handle.net/2445/183119 | - |
dc.description.abstract | Background: Interferon-p is an attractive drug for repurposing and use in the treatment of COVID-19, based on its in vitro antiviral activity and the encouraging results from clinical trials. The aim of this study was to analyze the impact of early interferon-p treatment in patients admitted with COVID-19 during the first wave of the pandemic. Methods: This post hoc analysis of a COVID-19@Spain multicenter cohort included 3808 consecutive adult patients hospitalized with COVID-19 from 1 January to 17 March 2020. The primary endpoint was 30-day all-cause mortality, and the main exposure of interest was subcutaneous administration of interferon-beta, defined as early if started <= 3 days from admission. Multivariate logistic and Cox regression analyses were conducted to identify the associations of different variables with receiving early interferon-beta therapy and to assess its impact on 30-day mortality. A propensity score was calculated and used to both control for confounders and perform a matched cohort analysis. Results: Overall, 683 patients (17.9%) received early interferon-p therapy. These patients were more severely ill. Adjusted HR for mortality with early interferon-p was 1.03 (95% CI, 0.82-1.30) in the overall cohort, 0.96 (0.82-1.13) in the PS-matched subcohort, and 0.89 (0.60-1.32) when interferon-beta treatment was analyzed as a time-dependent variable. Conclusions: In this multicenter cohort of admitted COVID-19 patients, receiving early interferon-beta therapy after hospital admission did not show an association with lower mortality. Whether interferon-beta might be useful in the earlier stages of the disease or specific subgroups of patients requires further research. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.biopha.2021.112572 | - |
dc.relation.ispartof | Biomedicine & Pharmacotherapy, 2022, vol 146 | - |
dc.relation.uri | https://doi.org/10.1016/j.biopha.2021.112572 | - |
dc.rights | cc by-nc-nd (c) Salto Alejandre, Sonsoles et al, 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | Terapèutica | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | Therapeutics | - |
dc.title | Impact of Early Interferon-β Treatment on the Prognosis of Patients with COVID-19 in the First Wave: A Post Hoc Analysis from a Multicenter Cohort | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-02-11T11:47:10Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34954640 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0753332221013597-main.pdf | 796.72 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License